Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) - A phase III study. von Lewinski D, Tripolt NJ, Sourij H, Pferschy PN, et al. Am Heart J 2022;246:152-160.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

von Lewinski D, Tripolt NJ, Sourij H, Pferschy PN, et al. Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) - A phase III study. Am Heart J 2022;246:152-160.
PMID: 35045327